**CRADA Letter of Intent from EPA Delegated Authority to**

**Sarah Bauer, FTTA Coordinator**

1. **EPA Laboratory(ies)/Office(s)/Region(s)**
2. **Proposed Cooperator(s):**
3. **Please describe the R&D to be conducted under the CRADA, including the collaboration involved and any possible intellectual property to be created (patents or copyrightable subject matter such as software).**

**[ ] Patents [ ] Intellectual Property**

**[ ] Software [ ] Other Copyrightable Subject Matter**

**[ ] Other (describe):**

**4. Type of Cooperator: (Indicate all that apply)**

**[ ] Trade Association [ ] Corporation (size: [ ] small [ ] mid-size [ ] large)**

**[ ] Consortia [ ] State govt. [ ] Non-Profit [ ] University (type): [ ] State [ ] Private**

**[ ] Minority Owned Business [ ] Woman Owned Business**

**[ ] Other (describe):\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Number of Employees:**

**State or Country of Incorporation:**

**How long has the cooperator been in business:**

**Principal place of business:**

**If corporation, please identify parent corporation, if any, as well as Parent’s State or Country of Incorporation:**

**5. How long do you plan for the CRADA to last?**

**6.a. For the estimated duration of the CRADA, what is the Laboratory’s proposed contribution toward R&D activities to be conducted under the CRADA? (Indicate all that apply):**

**[ ] Patent, copyright or Trademark rights/licenses**

**[ ] Technical Assistance [ ] Facilities [ ] Supplies [ ] Laboratory Studies**

**[ ] Contractor Support [ ] Modeling [ ] Field Work/Sampling**

**[ ] Durable Equipment to be retained by Cooperator [ ] Other (please specify)**

**6.b. For the estimated duration of the CRADA, what is the Laboratory’s proposed FTE contribution toward R&D activities to be conducted under the CRADA?**

**Full-time Equivalent EPA estimate (over life of agreement):**

**Researcher name(s):**

**7. For the estimated duration of the CRADA, what is the Cooperator’s proposed contribution toward R&D activities to be conducted under the CRADA? (Indicate all that apply):**

**[ ] Patent, copyright or Trademark rights/licenses**

**[ ] Technical Assistance [ ] Facilities [ ] Supplies [ ] Funds**

**[ ] Laboratory Studies [ ] Contractor Support**

**[ ] Modeling [ ] Field Work/Sampling**

**[ ] Durable Equipment to be retained by Cooperator [ ] Other (please specify)**

**8. Value of EPA’s estimated total contribution (in-kind) $**

**Value of Cooperator’s estimated contribution (in-kind) $**

**Cooperator’s cash contribution to EPA $**

**Cooperator’s total contribution (cash and in-kind) $**

**9. Use of funds received under the CRADA. (Indicate all that apply)**

**[ ] Travel [ ] Supplies [ ] Personnel expenses**

**[ ] Laboratory expenses [ ] Support to contractor**

**[ ] None [ ] Other (please specify)**

**10. The potential benefit the Laboratory or the Agency will derive from the**

**specific Agreement and in the future, including any IP rights/licenses.**

**11. The potential benefit the Cooperator will derive from the agreement, including any IP rights/licenses.**

**12. Which party initiated the collaboration?**

**[ ] EPA [ ] Cooperator**

**12(a). If EPA initiated the collaboration, was the collaboration announced to the general public or the identified industry? If so, where was it announced (give specific citation).**

**12(b). If the collaboration was not announced to the general public or the identified industry, explain why announcement was not practical or describe what was done to ensure fairness in the selection of the Cooperator:**

**13. Cooperator has the following arrangement(s) with EPA: (Indicate all that apply)**

**[ ] Contracts [ ] Grants/Cooperative Agreements [ ] CRADAs [ ] Licenses**

**[ ] MTAs [ ] Voluntary Partnership [ ] None [ ] Other (please specify)**

**14. Are any of the ones checked above related to this proposed CRADA?**

**[ ] No [ ] Yes (please explain)**

**15. Which of EPA’s strategic goals does the purpose of this research support? (Please describe both the purpose and identify the goal).**

**For questions 16-19 ORD only, unless applicable**

**16. Is this research reflected in a specific Office or Regional research or science plan? If so, which plan?**

**17. What National Research Program does this work address?**

**[ ] Air, Climate, Energy (ACE) [ ] Safe & Sustainable Waters (SSW)**

**[ ] Chemical Safety for Sustainability (CSS) [ ] Sustainable &Healthy Communities (SHC)**

**[ ] Human Health Risk Assessment (HHRA) [ ] Homeland Security (HS)**

**[ ] None [ ] Other (please specify)**

**18 Under the RAP, what Goal, Science Question and Outcome does this work address?**

**Air, Climate and Energy**

[  ] Theme 1     [  ] Theme 2   [  ]  Theme 3

Science Question(s) :  [            ]

Output(s):          [           ]

**Safe and Sustainable Water Resources**

[  ] Theme 1     [  ] Theme 2

Science Question(s) :  [            ]

Output(s):          [           ]

**Sustainable and Healthy Communities**

[  ] Theme 1     [  ] Theme 2   [  ]  Theme 3   [   ]  Theme 4

Topic(s) :  [            ]

Output(s): [           ]

**Chemical Safety for Sustainability**

[  ] Theme 1     [  ] Theme 2   [  ]  Theme 3   [   ]  Theme 4

[  ] Theme 5     [  ] Theme 6   [  ]  Theme 7   [   ]  Theme 8

Science Question(s) :  [            ]

Output(s):          [           ]

**Human Health Risk Assessment**

[  ] Theme 1     [  ] Theme 2   [  ]  Theme 3   [   ]  Theme 4

Science Question(s) :  [            ]

Output(s): [                                                                 ]

**Homeland Security**

[  ] Theme A    [  ] Theme  B   [  ]  Theme  C

Science Question(s) :  [            ]

Output(s): [                                                                 ]

**19. If the data or material that are being transferred constitute human subjects research, please visit the following intranet site to determine if your project needs review and approval by the HSRRO:** [**http://intranet.ord.epa.gov/p2/hsr/human-subjects-review**](http://intranet.ord.epa.gov/p2/hsr/human-subjects-review)

**20. The Dual Use Research of Concern (DURC) Internal Review Entity (IRE) has determined that:**

**□ this research does not meet the DURC definition and no additional review and oversight are required. The PI must report to the IRE any results or changes in the research such that one or more of the 7 categories of experimental effects may apply, or if the PI feels that the research may be DURC.**

**□ this research meets the DURC definition and requires additional oversight under the *USG Policy for Institutional Oversight of DURC*. Corresponding USG funding agency will be notified and a draft of the mitigation plan will be submitted within 90 days of this determination.**

**□ Mitigation Plan submitted to the funding agency on\_\_\_\_\_\_\_\_**

**□ Approved mitigation Plan on file**

**Please visit:** [**http://www.phe.gov/s3/dualuse/Pages/default.aspx**](http://www.phe.gov/s3/dualuse/Pages/default.aspx)

**21. To the best of your knowledge, are there any implications for current, pending, or prospective EPA:**

**[ ] Regulations;**

**[ ] Licenses;**

**[ ] Permits**

**[ ] Compliance or Enforcement Actions**

**[ ] Litigation**

**[ ] Sensitive Issues**

**If yes to any, please specify and discuss:**

**22. Identify any EPA Program Office(s) or Region(s) that could be affected or benefit by this CRADA:**

**EPA Program Office(s):**

**EPA Specific Region(s):**

**23. Cooperator understands that the EPA may post non-sensitive or non-confidential information regarding this effort on the EPA Internet site and include in outreach materials.**

**For questions regarding this proposed CRADA, contact:**

**Name:**

**Phone:**

SIGNATURE

I assert and attest that this Collaborative Research and Development Agreement (CRADA) effort has received clearance from the US EPA Human Subjects Experts where applicable (refer to Question #19).

I assert and attest that this Collaborative Research and Development Agreement (CRADA) effort is in compliance with the DURC Policy (September, 2014) and certify that parties to any FTTA agreement each have a DURC review process in place (ICDUR, IRE and reporting capability) before moving ahead with a FTTA Agreement. (refer to question #20).

**ORD ONLY** - RAP and MATRIX INTERFACE COORDINATION: I assert and attest that this Collaborative Research and Development Agreement (CRADA) effort has been discussed with the Matrix Interface for coordination with the National Program Director.

Signature:\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Printed Name:\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Title:\_\_Director, [NAME OF LABORATORY]\_\_\_\_**

**Date:\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**